RespireRx Pharmaceuticals Inc (fka RSPI)

[haysaw]

The FDA clamping down on analgesic product approvals, demanding REMS plans in the face of the abuse epidemic.

This trend actually should work in Corx's favor, if management played their cards right. Not only could it benefit Corx from the abuse angle (which concerns the FDA), but also from the liability angle vis-à-vis RD complications in surgical procedures (which would concern the doctors, drug cos, etc.).

I may be 'intellectually lazy' as you say, but clearly you are stretching too far to try and make a point.